@konlan_james's bloodwork adjustments fact-checked

What did @konlan_james actually say?

The creator shared recent bloodwork showing total testosterone at 1,478 ng/dL and free testosterone at 214.5 pg/mL while on a protocol combining enclomiphene and HCG through Transcend. He acknowledged estradiol was "a little high" at 78 pg/mL and said his provider added anastrozole (25mg) and DHEA (25mg every other day). He also listed his current stack as armored thyroid, IGF-1, BPC-157, TB-500, enclomiphene, and HCG. His core claim: testosterone that high is "not so much a problem" because he still feels good. He ended with a referral pitch for Transcend.

The video reads less like health education and more like a brand testimonial. That context matters when evaluating the medical claims embedded in it.

Does the science back this up?

Parts of it do, parts of it don't, and some of it raises real clinical flags that the creator glossed over. A testosterone level of 1,478 ng/dL is well above the adult male reference range of roughly 300-1,000 ng/dL. Feeling fine is not a reliable safety marker at that level.

Supraphysiologic testosterone is associated with erythrocytosis, elevated hematocrit, and cardiovascular strain. Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) showed dose-dependent increases in red blood cell mass at testosterone levels exceeding physiologic ranges. The creator mentioned C-reactive protein as a cardiac reassurance marker, which is reasonable, but CRP alone doesn't capture the full cardiovascular risk picture at these levels. Hematocrit, hemoglobin, and lipid trends over time matter more. He mentioned cholesterol and HDL/LDL looked good, which is worth something, but the specific values were not shared. Free testosterone at 214.5 pg/mL is also substantially elevated above typical reference ranges of 35-155 pg/mL for adult men, which amplifies androgenic effects.

The estradiol reading of 78 pg/mL is genuinely elevated for a man, and adding anastrozole makes clinical sense in that context, though the dose mentioned is not something this article will validate.

What did they get wrong (or right)?

He got the estradiol concern basically right. Elevated estradiol in men on testosterone protocols can contribute to gynecomastia and water retention, and aromatase inhibitor use in that context is a recognized clinical intervention. Credit where it's due.

What he got wrong, or at least dangerously understated: calling a testosterone level nearly 50% above the upper reference limit "not so much a problem" because subjective wellbeing is intact. Symptoms often lag behind biomarker risk. The Testosterone Trials (Snyder et al., 2016, New England Journal of Medicine) found cardiovascular signal concerns even at more moderate supraphysiologic levels. Feeling great is not a clinical safety endpoint.

The peptide stack also deserves scrutiny. BPC-157 and TB-500 are research compounds with no FDA approval and no established human dosing data. Presenting them casually alongside prescribed medications, as if they belong in the same category, blurs a meaningful regulatory and safety distinction. IGF-1 similarly carries significant risk context, including potential mitogenic effects, that the creator did not address at all.

What should you actually know?

If your testosterone comes back at 1,478 ng/dL on a monitored protocol, that is not a routine result to shrug off. Most clinical guidelines for TRT aim to bring levels into the mid-to-upper physiologic range, not past it. The Endocrine Society's 2018 clinical practice guidelines recommend targeting levels within the normal range, not above it, to minimize adverse effects.

The creator's framing, that optimization means pushing levels higher, reflects a philosophy common in the performance wellness space but not supported by safety-focused endocrinology literature. "We don't want just average, we want optimized" sounds compelling in a TikTok caption. It is not a clinical standard.

The peptides listed, BPC-157, TB-500, and IGF-1, are not FDA-approved drugs. They are not equivalent to prescribed medications. Anyone considering compounds like these should understand they exist outside the normal regulatory framework that provides safety and efficacy data. A telehealth provider endorsing them without that disclaimer is cutting corners on informed consent.

Finally, this video is a referral advertisement. The creator explicitly invites viewers to contact Transcend and mention his name. That commercial relationship should inform how you weigh the medical reassurance he offers.